Investment Q&A

HanchorBio focuses on next-generation immuno-oncology fusion protein biologics, leveraging our proprietary FBDB™ platform, advanced protein engineering, and AI-assisted drug design to tackle key challenges in cancer immunotherapy.
Key features of the FBDB™ platform include:
1. High Technological Sophistication: Proprietary Fc-based backbone enabling highly specific anti-cancer molecules through genetic engineering.
2. Unique Capability: HanchorBio is the only biotech company in Taiwan developing trifunctional biologics, competing directly with global pharmaceutical companies.
3. High Flexibility: Combining an Fc backbone and multi-targeting for diverse cancer indications.
4. Dual Immune Activation: Simultaneously triggers innate and adaptive immune responses with synergistic anti-tumor effects.
5. Proven Efficacy: Demonstrated safety and strong anti-cancer potential in preclinical studies.
6. Clear Mechanism of Action (MoA): Blocks tumor–immune signaling pathways, outperforming monoclonal and combination therapies.
7. Cost Efficiency: Consolidates multiple biologics into a single therapeutic, reducing R&D, manufacturing, and clinical costs.
8. Process Robustness: Mature manufacturing with high yield, high purity, and stability across various temperatures, suitable for cold-chain distribution and storage.

HanchorBio’s core product pipelines include:
HCB101 
Best-in-class (BIC) immuno-oncology biologic

• Primary Target: CD47 — Targeting multiple solid tumors and NHL, with clinical trials conducted at hospitals across Taiwan, the United States, and Mainland China.
•  Phase 1a: Monotherapy; high-dose safety confirmed; multiple patients showed significant tumor shrinkage (PR).
• Phase 1b/2 (Ongoing): Combination with SOC in head & neck cancer, Triple-negative breast cancer, gastric cancer, and colorectal cancer; further evidence of tumor shrinkage (PR, partial response).

HCB301
Next-generation tri-functional immuno-oncology biologic

• Primary Targets: CD47, PD-L1 & Tumor Microenvironment (TME) Modulators — Targeting multiple solid tumors and NHL.
•  Phase 1a: Monotherapy; IND approvals from U.S. FDA and China NMPA; first patient enrolled and dosed.

HCB303
Next-generation tri-functional immuno-oncology biologic

• Primary Targets: CD47, PD-L1 & a third target — Focused on multiple solid tumors and NHL, currently in late-stage development and expected to enter clinical trials. Other projects: Novel biologics targeting innate immunity, adaptive immunity, and the tumor microenvironment (TME).

1.  High Safety: Preclinical primate studies confirmed safety; no anemia or transfusion-related adverse events.
2.  Broad Anti-Cancer Potential: Preclinical cell and animal studies showed >80% tumor reduction across multiple cancer types.
3. Entering Phase 1b/2 global multi-regional, multi-center trials: Conducted across multiple hospitals in the United States, Mainland China, and Taiwan, testing anti-cancer efficacy across diverse patient populations and multiple tumor types.

For solid tumors, clinical trials have demonstrated efficacy unmatched by competitors: in multi-cancer clinical studies, monotherapy achieved tumor shrinkage of over 30% in cancer patients.

Currently, we are focused on advancing our R&D programs and generating clinical data. Any IPO plan will be evaluated based on pipeline maturity and capital market conditions, and announcements will be made at public investor briefings if applicable.

HanchorBio has completed multiple private financing rounds and was listed on the Taipei Emerging Stock Board (June 2025)(7827. TWO). General investors can now participate via the public market. For future financing or investment opportunities, please contact:
📩 [email protected]

Recent financial summaries are available under the “Annual Financial Statements” section of this website. Full statements are filed with regulatory authorities or can be requested via our Finance Department.

Short-, Medium-, and Long-Term Objectives:

•  Complete global multi-center Phase 1b/2 clinical trials of HCB101.
•  Complete global multi-center Phase 1a trials of HCB301.
• Submit IND application for the third oncology biologic program.
•  Expand translational medicine and clinical validation teams.
• Explore potential licensing and co-development partnerships.

Additional updates will be announced at investor conferences or progress briefings.